Document is current
Any future updates will be listed below
-
Authors
Wang, Yujia https://orcid.org/0000-0002-5264-521X
Casarin, Stefano
Daher, May https://orcid.org/0000-0002-6026-8397
Mohanty, Vakul https://orcid.org/0000-0002-5536-6750
Dede, Merve https://orcid.org/0000-0002-0868-5863
Shanley, Mayra https://orcid.org/0000-0003-3739-0287
Dondossola, Eleonora
La Posta, Ludovica https://orcid.org/0009-0001-7850-4925
Başar, Rafet https://orcid.org/0000-0003-4713-0454
Rezvani, Katayoun https://orcid.org/0000-0002-9599-2246
Chen, Ken https://orcid.org/0000-0003-4013-5279
- License Information
-
More Information
Article History
Received: 26 March 2025
Accepted: 27 January 2026
First Online: 11 February 2026
Competing interests
: The authors declare the following competing interests: M.Da., R.B., M.S., and K.R., and the University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical. R.B., K.R., and the University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Affimed GmbH. K.R. participates on the Scientific Advisory Board for Avenge Bio, Virogin Biotech, Navan Technologies, Caribou Biosciences, Bit Bio Limited, Replay Holdings, oNKo Innate, and The Alliance for Cancer Gene Therapy ACGT. K.R. is the Scientific founder of Syena. M. Da. participates on the Scientific Advisory Board for Cellsbin.
